Neuroprotection for optic nerve disorders

Current Opinion in Neurology

Volumn 23, Issue 1, 2010, Pages 10-15

  Bessero, Anne Caroline ^a   Clarke, Peter G H ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Excitotoxicity; Glaucoma; Neuroprotection; Neurotrophin; Retinal ganglion cells

Indexed keywords

ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR P75;

AUTOIMMUNE DISEASE; CELL DEATH; ENZYME INHIBITION; GLAUCOMA; GLIA CELL; HUMAN; INFLAMMATION; INFRARED RADIATION; INTRAOCULAR PRESSURE; NERVE CELL EXCITABILITY; NERVE DEGENERATION; NEUROPROTECTION; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; RADIATION EXPOSURE; REVIEW;

ANTIOXIDANTS; GLAUCOMA; HUMANS; INFRARED RAYS; INTRAOCULAR PRESSURE; NITRIC OXIDE SYNTHASE; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS; UBIQUINONE;

EID: 74049109447     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283344461     Document Type: Review

References (58)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844-851.
2. Mackenzie P, Cioffi G. How does lowering of intraocular pressure protect the optic nerve? Surv Ophthalmol 2008; 53 (Suppl 1):S39-S43.
3. Winkler M, Jester B, Nien-Shy C, et al. High resolution three-dimensional reconstruction of the collagenous matrix of the human optic nerve head. Brain Res Bull 2009 [Epub ahead of print].
4. Pemp B, Georgopoulos M, Vass C, et al. Diurnal fluctuation of ocular blood flow parameters in patients with primary open-angle glaucoma and healthy subjects. Br J Ophthalmol 2009; 93:486-491.
5. Leske MC. Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. Curr Opin Ophthalmol 2009; 20:73-78.
6. Hazin R, Hendrick AM, Kahook MY. Primary open-angle glaucoma: diagnostic approaches and management. J Natl Med Assoc 2009; 101:46-50.
7. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, et al. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 2007; 68:1488-1494.
8. Koczman JJ, Rouleau J, Gaunt M, et al. Neuro-ophthalmic sarcoidosis: the University of Iowa experience. Semin Ophthalmol 2008; 23:157-168.
9. Plant GT. Optic neuritis and multiple sclerosis. Curr Opin Neurol 2008; 21:16-21.
10. Levin LA, Gordon LK. Retinal ganglion cell disorders: types and treatments. Prog Retin Eye Res 2002; 21:465-484.
11. Leung CK, Weinreb RN. Experimental detection of retinal ganglion cell damage in vivo. Exp Eye Res 2009; 88:831-836.
12. Barnett EM, Zhang X, Maxwell D, et al. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model. Proc Natl Acad Sci USA 2009; 106:9391-9396.
13. Danias J, Shen F, Kavalarakis M, et al. Characterization of retinal damage in the episcleral vein cauterization rat glaucoma model. Exp Eye Res 2006; 82:219-228.
14. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. Translimbal laser photocoagulation to the trabecular meshworkasamodel of glaucoma in rats. Invest Ophthalmol Vis Sci 2002; 43:402-410.
15. Johnson EC, Guo Y, Cepurna WO, Morrison JC. Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models. Exp Eye Res 2009; 88:808-815.
16. McKinnon SJ, Schlamp CL, Nickells RW. Mouse models of retinal ganglion cell death and glaucoma. Exp Eye Res 2009; 88:816-824.
17. Rosenbaum DM, Rosenbaum PS, Singh M, et al. Functional and morphologic comparison of two methods to produce transient retinal ischemia in the rat. J Neuroophthalmol 2001; 21:62-68.
18. Cooper NG, Laabich A, Fan W, Wang X. The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells. Prog Brain Res 2008; 173:521-540.
19. Morgan IG. Intraocular colchicine selectively destroys immature ganglion cells in chicken retina. Neurosci Lett 1981; 24:255-260.
20. Carson C, Saleh M, Fung FW, et al. Axonal dynactin p1 50Glued transports caspase-8 to drive retrograde olfactory receptor neuron apoptosis. J Neurosci 2005; 25:6092-6104.
21. Primi M-P, Clarke PGH. Early retrograde effects of blocking axoplasmic transport in the axons of developing neurons. Dev Brain Res 1997; 99:259-262.
22. Singer PA, Mehler S, Fernandez HL. Blockade of retrograde axonal transport delays the onset of metabolic and morphologic changes induced by axotomy. J Neurosci 1982; 2:1299-1306.
23. Mader K, Andermahr J, Angelov DN, Neiss WF. Dual mode of signaling of the axotomy reaction: retrograde electric stimulation or block of retrograde transports differently mimic the reaction of motoneurons to nerve transection in the rat brainstem. J Neurotrauma 2004; 21:956-968.
24. Casson RJ. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Experiment Ophthalmol 2006; 34:54-63.
25. Moreno MC, Sande P, Marcos HA, et al. Effect of glaucoma on the retinal glutamate/glutamine cycle activity. FASEB J 2005; 19:1161-1162.
26. Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs 2007; 67:725-759.
27. Ullian EM, Barkis WB, Chen S, et al. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci 2004; 26:544-557.
28. Nakanishi N, Tu S, Shin Y, et al. Neuroprotection by the NR3A subunit of the NMDA receptor. J Neurosci 2009; 29:5260-5265.
29. Lebrun-Julien F, Duplan L, Pernet V, et al. Excitotoxic death of retinal neurons in vivo occurs via a noncell-autonomous mechanism. J Neurosci 2009; 29:5536-5545.
30. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26:12633-12641.
31. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205:2473-2481.
32. Wax MB, Tezel G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp Eye Res 2009; 88:825-830.
33. Stasi K, Nagel D, Yang X, et al. Complement component 1Q (C1Q) upregula-tion in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci 2006; 47:1024-1029.
34. Kuehn MH, Kim CY, Ostojic J, et al. Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res 2006; 83:620-628.
35. Wax MB, Tezel G, Yang J, et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci 2008; 28:12085-12096.
36. Clarke PGH. Apoptosis versus necrosis. How valid a dichotomy for neurons? In: Kaliotsos VE, Ratan RR, editors. Cell death and diseases of the nervous system. Totowa, NJ: Humana Press Inc; 1999. pp. 3-28.
37. Agudo M, Perez-Marin MC, Sobrado-Calvo P, et al. Immediate upregulation of proteins belonging to different branches of the apoptotic cascade in the retina after optic nerve transection and optic nerve crush. Invest Ophthalmol Vis Sci 2009; 50:424-431.
38. Nickells RW, Semaan SJ, Schlamp CL Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death. Prog Brain Res 2008; 173:423-435.
39. Azuma M, Shearer TR. The role of calcium-activated protease calpain in experimental retinal pathology. Surv Ophthalmol 2008; 53:150-163.
40. Munemasa Y, Ahn JH, Kwong JM, et al. Redox proteins thioredoxin 1 and thioredoxin 2 support retinal ganglion cell survival in experimental glaucoma. Gene Ther 2009; 16:17-25.
41. Munemasa Y, Ohtani-Kaneko R, Kitaoka Y, et al. Pro-apoptotic role of c-Jun in NMDA-induced neurotoxicity in the rat retina. J Neurosci Res 2006; 83:907-918.
42. Yang X, Luo C, Cai J, et al. Phosphorylation-dependent interaction with 14-3-3 in the regulation of bad trafficking in retinal ganglion cells. Invest Ophthalmol Vis Sci 2008; 49:2483-2494.
43. Guma M, Rius J, Duong-Polk KX, et al. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA 2009; 106:8760-8765.
44. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87:450-454.
45. Schmidt KG, BergertH, Funk RH. Neurodegenerative diseases of the retina and potential for protection and recovery. CurrNeuropharmacol 2008; 6: 164-178.
46. Weber AJ, Harman CD, Viswanathan S. Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina. J Physiol 2008; 586:4393-4400.
47. Parrilla-Reverter G, Agudo M, Sobrado-Calvo P, et al. Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study. Exp Eye Res 2009; 89:32-41.
48. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci USA 2009; 106:13469-13474.
49. Shi Z, Rudzinski M, Meerovitch K, et al. Alpha2-macroglobulin is a mediator of retinal ganglion cell death in glaucoma. J Biol Chem 2008; 283:29156-29165.
50. Lebrun-Julien F, Morquette B, Douillette A, et al. Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Mol Cell Neurosci 2009; 40:410-420.
51. Fu QL, Hu B, Wu W, et al. Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transec tion. Invest Ophthalmol Vis Sci 2008; 49:975-985.
52. Fu QL, Li X, Yip HK, et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 2009; 162:375-382.
53. Castagne V, Gautschi M, Lefevre K, et al. Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system. Prog Neurobiol 1999; 59:397-423.
54. Rojas JC, John JM, Lee J, Gonzalez-Lima F. Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy. Neurotox Res 2009; 15:260-273.
55. Inokuchi Y, Imai S, Nakajima Y, et al. Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo. J Pharmacol Exp Ther 2009; 329:687-698.
56. Russo R, Cavaliere F, Rombola L, et al. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection. Prog Brain Res 2008; 173:575-582.
57. Rojas JC, Lee J, John JM, Gonzalez-Lima F. Neuroprotective effects of near-infrared light in an in vivo model of mitochondrial optic neuropathy. J Neurosci 2008; 28:13511-13521.
58. Kim SJ, Kim YJ, Park KH. Neuroprotective effect of transpupillary thermo-therapy in the optic nerve crush model of the rat. Eye 2009; 23:727-733.